Cargando…
OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53
Background: Sorafenib (Nexavar(®)) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high doses limit the clinical application of sorafenib and strongly recommend its combination with other agents aiming at ameliorating...
Autores principales: | Omar, Hany A., Tolba, Mai F., Hung, Jui-Hsiang, Al-Tel, Taleb H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127788/ https://www.ncbi.nlm.nih.gov/pubmed/27965580 http://dx.doi.org/10.3389/fphar.2016.00463 |
Ejemplares similares
-
Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022) -
Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis
por: Liu, Zhi-Yong, et al.
Publicado: (2022) -
Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
por: Liu, Jianhua, et al.
Publicado: (2017) -
Polymer Nanoformulation of Sorafenib and All-Trans Retinoic Acid for Synergistic Inhibition of Thyroid Cancer
por: Li, Shijie, et al.
Publicado: (2020) -
Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)